1
Thank you to our sponsors!
2
Topics to be covered
ASCO 2023 Annual Meeting – June 2-6, Chicago
IMWG Summit – June 7-8, Frankfurt
EHA 2023 Hybrid Congress – June 9-12, Frankfurt
•
•
•
4
Notable Event: 2023 Kyle & Durie Achievement Awards
5
Congratulations!
Maria-Victoria Mateos, MD, PhD
Recipient of the 2023 Robert A. Kyle Lifetime Achievement Award
Thomas Martin, MD
Recipient of the 2023 Brian G.M. Durie Outstanding Achievement Award
Top Abstract
at ASCO and EHA (Plenary)
• Cilta-cel (CAR T) v SOC in Early Relapse presented during the Special CAR T Session at ASCO 2023
• Impressive results: Progression risk reduced by 74%
• Companion NEJM Publication: Points to use of CAR T in Earlier Disease
6
7
Impact of CAR T Therapy: CARTITUDE-4
RESULTS versus RRMM results (CARTITUDE-1)
9
10
11
ASCO: Main Oral Session
Saturday, June 3
• Abstract #8000: KRd vs Elo KRd in NDMM
• Abstract #8001: KPd maintenance in High-risk MM
• Abstract #8002: Teclistamab + Talquetamab (RedirecTT-1)*****
• Abstract #8003: Talquetamab + Dara (TRiMM-2)
• Abstract #8004: Phase 1 CAR T: PHE 885
• Abstract #8005: Rapid CAR T dual target – Shanghai experience
• Abstract #8006: Bispecific Regeneron #5458 (LINKER-MM1)
• Abstract #8007: DREAMM-3 Bela versus Pom dex F/U
• Abstract #8008: Bispecific Elranatamab: MagnetisMM
*****Will be discussed in full
13
Additional ASCO Presentations
SPECIAL POPULATIONS: Age/Disparities/Renal Compromise
Meet the Prof on Bispecifics: Moreau/Garfall
Wide range of topics
ORALS/POSTERS
•
•
•
14
EHA 2023 Presentations
Over 200 interesting/important Myeloma Abstracts!
Some TOP ABSTRACTS are also from ASCO 2023
Many unique presentations that are impossible to summarize:
Immune therapies (CAR T/Bispecifics)
Combinations
Real-world findings
Patient Preferences
Infections QoL DREAMM studies
Master Trial
Selinexor combos
Zometa 4 years
Young outcomes
Telomeres
EMD
Arginine Deprivation
MRD Surrogacy
•
•
•
15
17
19
21
22
23
24
26
Turning to IMWG Summit Key Discussions
28
Smoldering Multiple Myeloma Committee Report
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Shaji Kumar, MD Mayo Clinic
29
30
Endpoints for trials
• What would be the right endpoint for trials?
– Overall survival is the gold standard but will take many years to find the benefit
• Progression free survival?
• Sustained MRD negativity? If so, how long?
• HRQOL endpoints?
31
Combined Mass Spectrometry & MRD Committee Report
Mass Spectrometry
Brian G.M. Durie, MD
International Myeloma Foundation
David Murray, MD, PhD
Mayo Clinic
MRD
Nikhil Munshi, MD
Dana-Farber Cancer Institute
Bruno Pavia, PhD
University of Navarra
33
Mayo Update
• Performed over 200,000 tests by Mass Spec since 2018
– Retrospective review of first 20,000 tests published (Mayo Clinic Proceedings)
• Urine Mass Spec is clinically available as of two weeks ago
– Equal sensitivity to urine IFE without concentrating the urine
– Improved specificity as mass of light chains consistent with serum
• Elimination of SPEP Dec 2023
Literature Update
• Several New Papers using a targeted CDR M-protein peptides for MRD
– “Easy M” test from University of Washington in St. Louis
–
Sebia/Erasmus University MRD
• Detection in Non-Secretory MM (Giles et al Blood)
• Low-Cost Method using MALDi-TOF (Mehra et al)
Commercialization Update
• Europe planned for August 2023
• USA planned for Q1 2024
34
Why Mass Spec could be routine in
most labs
• Lab workflow/through put is significantly increased
–
Mayo has tripled the number of results per lab tech for IFE
– This will increase again on replacement of SPEP
• Current cost for U.S. Medicare patients is only 25% of a serum
rFLC determination
• Detection of other new entities and diseases
–
IgG4 RD patterns are recognizable by this method
– Replacement for oligoclonal banding for MS
–
M-protein light chain glycosylation
•
Amyloidosis
• Cold Agglutinin Disease
35
36
37
38
Guidelines to use MRD in clinical practice
Methods
39
•
• Frequency • Sampling •
• Patients
Time points
•
•
• Etc.
Reporting
Interpretation
IMWG Summit Takeaways
Many new projects (Registry/Biobank)
Publications pending/planned
New Areas of Focus:
o Infections and 2nd cancers
o QoL/Patients’ Perspective & Preferences
o Real-world role of MRD and Mass Spectrometry
o Many others for F/U before ASH Breakfast Meeting
41
“The Plasma Cells” IMWG Band
Zamagni,
Zweegman, MD, PhD; Philippe
MD; Paula Rodríguez-Otero, MD, PhD
42
From left to right: Francesca Gay MD, PhD; Alessandra La Rocca, MD, PhD; Elena
MD, PhD; Enrique Ocio, MD, PhD; S. Vincent Rajkumar, MD; Sonja
Moreau,
44
Video Replay
A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Videos Tab. A replay link will be directly emailed to all who registered for this webinar.
We Want to Hear From You!
Feedback Survey
At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey.
This will also be emailed to you shortly after the workshop.
Please take a moment to complete this survey.
